Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Bayer AG is conducting an observational study titled ‘Finerenone Research of Outcomes and Drug Utilization’ (FINEROD), focusing on the real-world use of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The study aims to gather data on the safety and effectiveness of finerenone, a recently approved treatment in the US, by analyzing existing health records from Japan and the United States.
Intervention/Treatment: The study examines the drug Finerenone (BAY 94-8862), which is used to block mineralocorticoid receptors, potentially reducing kidney, heart, and blood vessel damage in CKD and T2D patients.
Study Design: This is a retrospective, cohort observational study. It does not involve any intervention or specific advice, as it relies on existing electronic health records and claims data to assess the characteristics and outcomes of patients receiving finerenone.
Study Timeline: The study began on May 15, 2024, with data collection covering the period from July 1, 2021, to March 2024. The latest update was submitted on July 1, 2025, and the study is currently recruiting participants.
Market Implications: The ongoing study could influence Bayer’s stock performance by providing insights into finerenone’s effectiveness and safety, potentially boosting investor confidence. As finerenone is a novel treatment in a competitive market, positive results could enhance Bayer’s position in the CKD and T2D treatment landscape.
The study is ongoing, with further details available on the ClinicalTrials portal.